Therapy Areas: Vaccines
ReiThera's new production area granted operational authorisation in Italy
4 November 2022 -

ReiThera, an Italy-based biotech company, announced on Thursday that it has received operational authorisation from the Italian Medicines Agency (AIFA) to open the new production area at its pharmaceutical facility based in the Castel Romano Technopole.

The facility was set up for the large-scale production of viral vectors for vaccines and gene therapy. According to ReiThera it provides maximum flexibility in processing scale, able to accommodate GMP productions based on Adenovirus (Ad), Adeno-associated virus (AAV) and Lentivirus, starting from 50 litres up to a maximum of 3,000 litres.

Construction of the new production facility began in May 2020 with an investment of over EUR15m euros by ReiThera. This investment enabled the installation of the latest generation bioreactors with scaled volume capacities of 200, 1,000 and 2,000 litres.